Plain-English translation of NCT04234022 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This research trial is testing whether a medication called (also known as Imuthiol) can help treat multiple myeloma, a type of blood cancer. Researchers will take small bone marrow samples from patients and test how the medication works alone or combined with other existing treatments. The goal is to understand whether this approach might improve outcomes for people with myeloma.
Multiple myeloma is a serious blood cancer that often comes back after initial treatment. Researchers believe that this medication may work against a specific pathway in cancer cells that helps them survive and resist treatment, which could lead to better options for patients whose disease has relapsed or become resistant to standard drugs.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be asked to donate an extra 2–3 milliliters of bone marrow during a routine bone marrow test you're already having as part of your regular cancer care (at diagnosis and again if your disease returns). Your bone marrow sample will be sent to a lab where researchers will test how the medication performs. Your clinical information (age, diagnosis date, stage, previous treatments) will be collected and kept private while the lab analysis happens.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United Kingdom
The Royal Wolverhampton Hospitals NHS Trust
Collaborators
University of Wolverhampton
Enrollment target
~70 participants
Started
October 2021
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Supratik Basu
The Royal Wolverhampton NHS Trust
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.